Search Results - "Heier JS"

Gene therapy for AMD: better as an adjuvant than a replacement - Authors' reply.

Authors: Campochiaro PA Avery RL Brown DM et al.

Source: Lancet (London, England) [Lancet] 2025 Mar 08; Vol. 405 (10481), pp. 781-782.

Publication Type: Letter

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE; In Process

Real-World 6-Month Treatment Outcomes of Faricimab in Turkey: The FARTURK Study.

Authors: Çakır, Akın Akkan, Fevzi Kapran, Ziya et al.

Source: Ophthalmology & Therapy. Mar2026, Vol. 15 Issue 3, p1165-1177. 13p.

A Phase III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea^® in Patients with Wet Age-Related Macular Degeneration.

Authors: Bansal, Mudit Singh, Punit Mehta, Ruchi K. et al.

Source: Ophthalmology & Therapy. Feb2026, Vol. 15 Issue 2, p803-816. 14p.

Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Türkiye: 48-Month Data, BOSPHORUS-DME Study Group Report No. 1.

Authors: Özal, Ece Özkaya, Abdullah Arıcı, Murat et al.

Source: Turkish Journal of Ophthalmology / Türk Oftalmoloji Dergisi. Feb2026, Vol. 56 Issue 1, p1-10. 10p.

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice.

Authors: Debourdeau, Eloi Beylerian, Helene Nguyen, Vuong et al.

Source: Ophthalmology & Therapy. Sep2024, Vol. 13 Issue 9, p2343-2355. 13p.

Place of New Anti-Vascular Endothelial Growth Factor Agents in Recalcitrant Radiation Maculopathy: Case Reports.

Authors: Ural Fatihoglu, Özlem Tunc, Murat Saatci, Ali Osman

Source: Case Reports in Ophthalmology. Apr2026, Vol. 17 Issue 1, p583-595. 13p. 4 Illustrations, 1 Chart.

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Authors: Kitay, Alice M. Tillmann, Anne Pfister, Isabel et al.

Source: Ophthalmology & Therapy. Apr2026, Vol. 15 Issue 4, p1375-1388. 14p.

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Authors: Grimaldi, Gabriela Bartolomeo, Nicolò Garweg, Justus G. et al.

Source: Ophthalmology & Therapy. Mar2026, Vol. 15 Issue 3, p1069-1082. 14p.

Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON.

Authors: Loewenstein, Anat Schmidt-Ott, Ursula Do, Diana V. et al.

Source: Ophthalmology & Therapy. Jul2026, Vol. 15 Issue 7, p2441-2456. 16p.

Functional Real-World Outcomes of Aflibercept 8 mg Versus Faricimab After Loading Phase in Diabetic Macular Edema.

Authors: Menna, Feliciana Calabro, Mattia Guillot, Antonio et al.

Source: Ophthalmology & Therapy. Jul2026, Vol. 15 Issue 7, p2245-2254. 10p.

Durability of Three Monthly Loading Doses with Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration.

Authors: Turan, Leyla Bjerager, Jakob Subhi, Yousif et al.

Source: Ophthalmology & Therapy. Jun2026, Vol. 15 Issue 6, p2051-2061. 11p.

Comparison of the Syringe Preparation Time for Ranibizumab Prefilled Syringe versus Bevacizumab, Ranibizumab, and Aflibercept Vials.

Authors: Somuncu, Ahmet Mehmet Uğurlu, Adem Taşlı, Nurdan Gamze et al.

Source: Archives of Basic & Clinical Research. 2026, Vol. 8 Issue 2, p189-193. 5p.

Patient and Physician Perspectives on the Management of Diabetic Macular Edema.

Authors: Warren, Bernadette Donohoe, Michael Sivaprasad, Sobha et al.

Source: Ophthalmology & Therapy. Jan2026, Vol. 15 Issue 1, p21-33. 13p.

Safety of íntravitreal panitumumab combined with intravitreal ranibizumab in rabbits.

Authors: Bikbov, Mukharram M. Kazakbaeva, Gyulli M. Valishin, Iskander D. et al.

Source: PLoS ONE. 12/16/2025, Vol. 20 Issue 12, p1-10. 10p.

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Authors: Tillmann, Anne Stillenmunkes, Richard Garweg, Justus G. et al.

Source: Ophthalmology & Therapy. Dec2025, Vol. 14 Issue 12, p3079-3091. 13p.

Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial.

Authors: Brown, David M. Wolf, Sebastian Veselovsky, Milan et al.

Source: Ophthalmology & Therapy. Nov2025, Vol. 14 Issue 11, p2769-2783. 15p.

Risk Factors for Intraocular Lens Dislocation Requiring Surgical Intervention After Initial Phacoemulsification Cataract Surgery.

Authors: Karimaghaei, Sam Shakarchi, Ahmed F Shakarchi, Fatma F et al.

Source: Clinical Ophthalmology. Apr2026, Vol. 20, p1-10. 10p.

Therapeutic Equivalence of Eyluxvi (Aflibercept) to Eylea in Neovascular Age-Related Macular Degeneration: ALTERA Trial (Randomized).

Authors: Raczynska, Dorota Ernest, Jan Baumane, Kristine et al.

Source: Ophthalmology & Therapy. Feb2026, Vol. 15 Issue 2, p887-899. 13p.

Ocular gene therapy for neovascular AMD: a new era? - Authors' reply.

Authors: Campochiaro PA Heier JS Kherani S et al.

Source: Lancet (London, England) [Lancet] 2017 Nov 11; Vol. 390 (10108), pp. 2140. Date of Electronic Publication: 2017 Nov 09.

Publication Type: Letter; Comment

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States.

Authors: Baljoon A Diaby V Suther S et al.

Source: PharmacoEconomics - open [Pharmacoecon Open] 2026 May; Vol. 10 (3), pp. 457-469. Date of Electronic Publication: 2026 Mar 06.

Publication Type: Journal Article

Journal Info: Publisher: Springer International Publishing AG Country of Publication: Switzerland NLM ID: 101700780 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2509-4254 (Electronic) Linking ISSN: 25094262 NLM ISO Abbreviation: Pharmacoecon Open Subsets: PubMed not MEDLINE